血管紧张素Ⅱ1型受体抑制剂对人子宫内膜癌裸鼠皮下移植瘤的实验研究

摘要

Objective To explore angiotensin Ⅱ type Ⅰ receptor ( ATIR) inhibitor's influcnrc on cndomctrial c.ircinom.i transplanted tumor. Methods Female nude mouse aged 6 to 8 weeks were sclcetcd md were given cndomctrial carcinoma HEC 1B cell suspension. The cndomctrial c.ircinoma transpl.mtcd tumor model was randomly divided into tumor group md tumor suppression group, each hid 6 cascs. The tumor group was treated by normal salinc. The tumor suppression group was treatcd by AT1R inhibitor. Tumor formation conditions were observed , pithological examination of trans plmtcd tumor and tumor microvascular density (MVI)) and positive incidence of vascular cndothclial growth factor ( VEGF) was mcisiircd. Results Tell strain was successfully inoculated ,endometrial carcinoma tr.mspl.mtcd tumor mod el and AT1R inhibitor model were successfully established. There was significant difference between the two groups in tumor size with P<0.05. Tumor group, maximum diameter was 11.34 mm,the maximum volume was 448. 11mm3, was 216.16 mm3 ,average volume was 119. 13 mm3. Tumor stroma blood vessels of tumor suppression group were sig nificantly reduced with P<0.05. Positive incidence of VEGF of tumor suppression group was significantly lower than it of tumor group with P<0. 05. Conclusion AT1R inhibitor em obviously inhibit the form.ition of tumor stroma blood vessels,lead to inhibition of the growth of tumors md tissue of tumour necrosis. Therefore ATI R inhibitor in malignant tumor treatment plays the role of inhibition of tumor growth.%目的 探讨血管紧张素II1型受体(angiotensin II type 1 receptor,AT1R)抑制剂对人子宫内膜癌移植瘤的影响.方法 选择6～8周龄的雌性裸鼠,注射人子宫内膜癌HEC-1B细胞悬液,建立人子宫内膜癌移植瘤模型后,随机平均分为肿瘤组和肿瘤抑制组.观察成瘤情况,并对瘤组织进行病理组织学检查,肿瘤微血管密度(microvessel density,MVD)和VEGF阳性率测定.结果 细胞株被成功接种于裸鼠体内,裸鼠皮下移植瘤和AT1R抑制剂模型成功建立.两组模型中移植瘤的大小比较有明显差异(P＜0.05),肿瘤组最大直径为11.34 mm,最大体积为448.11 mm3,平均体积210.56 mm3;肿瘤抑制组最大直径9.01 mm,最大体积216.46 mm3,平均体积119.13 mm3.两组移植瘤中MVD比较,肿瘤抑制组肿瘤间质血管明显减少(P＜0.05).两组移植瘤中VEGF表达情况比较,肿瘤抑制组阳性率显著低于肿瘤组(P＜0.05).结论 AT1R抑制剂能够明显抑制肿瘤组织间质内血管的生成,从而抑制肿瘤的生长和导致肿瘤组织的坏死,因此AT1R抑制剂在恶性肿瘤的治疗方面起着抑制肿瘤生长的作用.